Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
暂无分享，去创建一个
M. Socinski | F. Cappuzzo | D. Moro-Sibilot | F. Barlesi | A. Sandler | M. Reck | M. Kowanetz | D. Rodríguez-Abreu | N. Nogami | A. López-Chávez | D. Stroyakovskiy | R. Jotte | G. Finley | F. Orlandi | Christian A Thomas | C. Kelsch | Anthony Lee | S. Coleman | Yijing Shen | C. Thomas | A. Lopez‐Chavez